Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Future Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/fon-2017-0392PMID 29243965
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity

  2017cited by this paper
• AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

  2017cited by this paper
• Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

  2017cited by this paper
• Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.

  2017cited by this paper
• Treatment of Relapsed/Refractory Acute Myeloid Leukemia

  2017cited by this paper
• Evaluating treatment patterns of relapsed acute myeloid leukemia (AML) among the elderly in the United States.

  2017cited by this paper
• Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 (mIDH2).

  2017cited by this paper
• Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

  2017cited by this paper
• The Emerging Hallmarks of Cancer Metabolism.

  2016cited by this paper
• Genomic Classification and Prognosis in Acute Myeloid Leukemia.

  2016cited by this paper
• Alpha-Ketoglutarate: Physiological Functions and Applications

  2016cited by this paper
• Acute myeloid leukemia in the older adults

  2016cited by this paper
• New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.

  2015cited by this paper
• Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

  2015cited by this paper
• International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

  2015cited by this paper
• Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

  2015cited by this paper
• Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

  2015cited by this paper
• International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.

  2014cited by this paper
• Abstract 2296: IDH2 mutation induced histone and DNA hypermethylation is progressively reversed by small molecule inhibition

  2014cited by this paper
• Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia

  2014cited by this paper
• Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.

  2014cited by this paper
• How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia.

  2014cited by this paper
• Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

  2013cited by this paper
• Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia.

  2013cited by this paper
• Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.

  2013cited by this paper
• IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives

  2012cited by this paper
• How I treat hematologic emergencies in adults with acute leukemia.

  2012cited by this paper
• Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

  2012cited by this paper
• The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.

  2011cited by this paper
• A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of αHG.

  2011cited by this paper
• Curing all patients with acute promyelocytic leukemia: are we there yet?

  2011cited by this paper
• The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases

  2011cited by this paper
• Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

  2011cited by this paper
• IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms

  2010cited by this paper
• Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

  2010cited by this paper
• Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

  2010cited by this paper
• Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.

  2010cited by this paper
• IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

  2010cited by this paper
• The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

  2010cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2010cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2009cited by this paper
• Puzzling Patterns of Predisposition

  2009cited by this paper
• Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

  2009cited by this paper
• The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

  2009cited by this paper
• Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: Causes and consequences

  2008cited by this paper
• Review Articles (434 articles)

  2008cited by this paper
• Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

  2003cited by this paper
• Control of Mitochondrial Redox Balance and Cellular Defense against Oxidative Damage by Mitochondrial NADP+-dependent Isocitrate Dehydrogenase*

  2001cited by this paper
• All-trans-retinoic acid in acute promyelocytic leukemia.

  1997cited by this paper
• Mediterranean Journal of Hematology and Infectious Diseases the Differentiation Syndrome I Experience of the Pethema Group

  year unknowncited by this paper

• Metabolites as signalling molecules in the tumour immune microenvironment.

  2026cites this paper
• 造血干细胞移植在急性髓系白血病中的应用进展

  2025cites this paper
• Green Ultra-Fast UPLC-MS/MS Method for Enasidenib Quantification in HLMs Matrix With the Metabolic Stability Assessment: In Silico Study for Structural Alerts, ADME Characteristics and Metaboslic Lability.

  2025cites this paper
• Mitochondrial Metabolomics in Cancer: Mass Spectrometry-Based Approaches for Metabolic Rewiring Analysis and Therapeutic Discovery

  2025cites this paper
• An Updated Overview of the Role of CYP450 during Xenobiotic Metabolization in Regulating the Acute Myeloid Leukemia Microenvironment

  2023cites this paper
• Safety and efficacy of immune checkpoint inhibitors after allogeneic hematopoietic cell transplantation

  2023cites this paper
• Mutant IDH in Gliomas: Role in Cancer and Treatment Options

  2023cites this paper
• Acute myeloid leukemia: challenges for diagnosis and treatment in Latin America

  2023influential citation
• Molecular mechanisms by which splice modulator GEX1A inhibits leukaemia development and progression

  2022cites this paper
• Novel benzo chromene derivatives: design, synthesis, molecular docking, cell cycle arrest, and apoptosis induction in human acute myeloid leukemia HL-60 cells

  2022cites this paper
• One‐Pot Multicomponent Synthesis ofBis(diamino‐1,3,5‐triazines) under Microwave Irradiation

  2022cites this paper
• Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment

  2022cites this paper
• Targeting mutations in cancer

  2022cites this paper
• Efficacy of non-intensive therapies approved for relapsed/refractory acute myeloid leukemia: a systematic literature review.

  2022cites this paper
• The beginning of a new therapeutic era in acute myeloid leukemia

  2021cites this paper
• Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer

  2021influential citation
• A New One-Pot Three-Component Synthesis of 4-Aryl-6-cycloamino-1,3,5-triazin-2-amines under Microwave Irradiation

  2021cites this paper
• Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

  2021cites this paper
• IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment

  2021cites this paper
• Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML

  2021cites this paper
• Treatment of Relapsed and Refractory AML: Non-intensive Approach in Unfit Patients

  2021cites this paper
• Black Disparities in Targeted Therapy Clinical Trials – A Call for Future Reset

  2021cites this paper
• Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application

  2020cites this paper
• Isocitrate Dehydrogenase 2 Inhibitors for the treatment of Hematologic Malignancies: Advances and Future Opportunities.

  2020cites this paper
• Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome

  2020cites this paper
• The Novel Phospholipid Mimetic KPC34 Is Highly Active Against Acute Myeloid Leukemia with Activated Protein Kinase C

  2020cites this paper
• 6,N2-Diaryl-1,3,5-triazine-2,4-diamines: synthesis, antiproliferative activity and 3D-QSAR modeling

  2020cites this paper
• Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia

  2020cites this paper
• Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors.

  2019cites this paper
• Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment

  2019cites this paper
• Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48 Hours of Sample Collection.

  2019cites this paper
• Targeting acute myeloid leukemia stem cell: current status and clinical application

  2019cites this paper
• Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics

  2019cites this paper
• Characteristics of Sweet's syndrome associated with novel acute myeloid leukemia targeted drugs—Midostaurin and Enasidenib

  2019cites this paper
• Prophylaxis and treatment of relapse after haploidentical stem cell transplantation: What is known vs unknown?

  2019cites this paper
• New agents in acute myeloid leukemia (AML)

  2019cites this paper
• Treatment of myelodysplastic syndrome in the era of next‐generation sequencing

  2019cites this paper
• Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs

  2019cites this paper
• Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects

  2018cites this paper
• Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas

  2018cites this paper
• Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations

  2018cites this paper
• The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China.

  2018cites this paper